UBS Still Neutral on East West Bank (EWBC)
East West Bancorp Inc. (NASDAQ:EWBC) is one of the 10 Best Bank Stocks to Buy in 2026.
UBS, on February 4, marginally trimmed its target price on East West Bancorp (EWBC) to $125 (from $126). Despite the target price cut, the firm retained its Neutral call on the stock, as it updated its bank models following the release of Q4 2025 results. The firm noted that mid-cap banks as a whole performed strongly in the previous quarter, avoiding credit risk concerns. It also noted that investor sentiment on regional banks is likely to remain high, supported by a steepening yield curve, accelerating loan growth, and increased M&A activity, such as Santander’s (SAN) acquisition of Webster (WBS).
EWBC reported its earnings on January 22. The company grew its Q4 net income by 21.5% YoY to $356.3 million (from $293.1 million), which led to a 103-basis point YoY improvement in the bank’s return on average common equity (from 15.08% points to 16.11% points). This strong result allowed EWBC to raise its quarterly dividend by 33% to $0.80 (from $0.60) and translated into a 15.9% YoY growth in its book value per share (from $55.79 to $64.68).
The earnings growth was driven primarily by an 11.9% YoY growth in net interest income (NII) (from $588 million to $658 million), which in turn was driven by both net interest margin (NIM) expansion and loan growth. NIMs rose 17 basis points to 3.41% (from 3.24%), as the bank’s cost of deposits fell 43 basis points to 2.16% (from 2.59%). The lower cost of funds from deposits more than offset the ~31-basis point decline in average loan yields (from 6.51% to 6.20%).
Loan book, meanwhile, grew 6.0% YoY to $56.9 billion (from $53.7 billion). For 2026, the bank’s management is expecting a 5% to 7% YoY increase in both loans and net interest income.
East West Bancorp Inc. (NASDAQ:EWBC) is a holding company that operates East West Bank. The company has two main operating segments: Consumer Banking and Commercial Banking. It is based in Pasadena, California, and was founded in August 1998.
While we acknowledge the potential of EWBC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Cheap Stocks to Buy Right Now and Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy.
Disclosure: None. This article is originally published at Insider Monkey.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
